CABL001J1US01 (ASC4REAL-2): A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

Objective

Clinical Trial Details

Clinical Trial Categories

  • Cancer
  • Leukemia
Contact
Hematology Research Coordinators at 605-322-3090
or hematologyresearch@avera.org

Location

  • Avera Cancer Institute — Mitchell
    605 N Foster St
    Mitchell, SD 57301
    Main: 605-995-5756
  • Avera Cancer Institute — Yankton
    1115 W 9th St
    Yankton, SD 57078
    Main: 605-668-8850
  • Avera Cancer Institute — Sioux Falls
    1000 E 23rd St
    Suite 340
    Sioux Falls, SD 57105
    Main: 605-322-3000
  • Avera Cancer Institute — Aberdeen
    310 S Penn St
    Suite 106
    Aberdeen, SD 57401
    Main: 605-622-8700
  • Avera Cancer Institute — Marshall
    300 S Bruce St
    Marshall, MN 56258
    Main: 507-537-9000
  • Avera Cancer Institute — Pierre
    801 E Sioux Ave
    Pierre, SD 57501
    Main: 605-224-3370